Literature DB >> 11953346

The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.

N J Talley1, K Lauritsen.   

Abstract

Dyspepsia is a common condition in the general population but data are lacking on the benefits of effective acid inhibition with proton pump inhibitors in functional dyspepsia. The results of the large, randomised, double blind clinical trials, BOND and OPERA, the Scandinavian PILOT study, and a follow up study, ENCORE, are reviewed. BOND, OPERA, and PILOT aimed to address the question of whether effective acid inhibition with the proton pump inhibitor omeprazole relieves symptoms in patients with functional dyspepsia. ENCORE followed on from this, addressing the consequences of relieving symptoms in patients with functional dyspepsia once they are off therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953346      PMCID: PMC1867693          DOI: 10.1136/gut.50.suppl_4.iv36

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

Review 1.  How should Helicobacter pylori negative patients be managed?

Authors:  V Stanghellini; C Tosetti; R De Giorgio; G Barbara; B Salvioli; R Corinaldesi
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

2.  Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis.

Authors:  M J Collen; M J Loebenberg
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

3.  Dyspepsia and dyspepsia subgroups: a population-based study.

Authors:  N J Talley; A R Zinsmeister; C D Schleck; L J Melton
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

4.  Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.

Authors:  A L Blum; R Arnold; M Stolte; M Fischer; H R Koelz
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

5.  Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia.

Authors:  A A George; M Tsuchiyose; C P Dooley
Journal:  Gastroenterology       Date:  1991-07       Impact factor: 22.682

6.  The "epigastric distress syndrome". A possible disease entity identified by history and endoscopy in patients with nonulcer dyspepsia.

Authors:  O Nyrén; H O Adami; S Gustavsson; P G Lindgren; L Lööf; A Nyberg
Journal:  J Clin Gastroenterol       Date:  1987-06       Impact factor: 3.062

7.  Endoscopic findings and diagnoses in unselected dyspeptic patients at a primary health care center.

Authors:  I Kagevi; S Löfstedt; L G Persson
Journal:  Scand J Gastroenterol       Date:  1989-03       Impact factor: 2.423

Review 8.  Non-ulcer dyspepsia: potential causes and pathophysiology.

Authors:  N J Talley; S F Phillips
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

Review 9.  Drug treatment of functional dyspepsia.

Authors:  N J Talley
Journal:  Scand J Gastroenterol Suppl       Date:  1991

10.  Blocked and nonblocked acid secretion and reported pain in ulcer, nonulcer dyspepsia, and normal subjects.

Authors:  S Bates; P O Sjödén; J Fellenius; O Nyrén
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

View more
  13 in total

1.  Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.

Authors:  Yoshikazu Kinoshita; Hiroto Miwa; Katsuyuki Sanada; Koji Miyata; Ken Haruma
Journal:  J Gastroenterol       Date:  2013-05-08       Impact factor: 7.527

2.  Proton-pump inhibitors for the treatment of functional dyspepsia.

Authors:  Hidekazu Suzuki; Sawako Okada; Toshifumi Hibi
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

Review 3.  New developments in the treatment of functional dyspepsia.

Authors:  Vincenzo Stanghellini; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Cesare Tosetti; Roberto Corinaldesi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.

Authors:  Tiing Leong Ang; Kwong Ming Fock; Eng Kiong Teo; Yiong Huak Chan; Tay Meng Ng; Tju Siang Chua; Jessica Yi-Lyn Tan
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

Review 5.  The Indications, Applications, and Risks of Proton Pump Inhibitors.

Authors:  Joachim Mössner
Journal:  Dtsch Arztebl Int       Date:  2016-07-11       Impact factor: 5.594

6.  Idiopathic Dyspepsia.

Authors:  Vincenzo Stanghellini; Elisabetta Poluzzi; Fabrizio De Ponti; Roberto De Giorgio; Giovanni Barbara; Roberto Corinaldesi
Journal:  Curr Treat Options Gastroenterol       Date:  2005-04

Review 7.  Drug treatment of functional dyspepsia.

Authors:  Klaus Mönkemüller; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

8.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

9.  Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia.

Authors:  Eyad M Salem; Talay Yar; Abdullah O Bamosa; Abdulaziz Al-Quorain; Mohamed I Yasawy; Raed M Alsulaiman; Muhammad A Randhawa
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

10.  Asian consensus report on functional dyspepsia.

Authors:  Hiroto Miwa; Uday C Ghoshal; Sutep Gonlachanvit; Kok-Ann Gwee; Tiing-Leong Ang; Full-Young Chang; Kwong Ming Fock; Michio Hongo; Xiaohua Hou; Udom Kachintorn; Meiyun Ke; Kwok-Hung Lai; Kwang Jae Lee; Ching-Liang Lu; Sanjiv Mahadeva; Soichiro Miura; Hyojin Park; Poong-Lyul Rhee; Kentaro Sugano; Ratha-Korn Vilaichone; Benjamin Cy Wong; Young-Tae Bak
Journal:  J Neurogastroenterol Motil       Date:  2012-04-09       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.